Boc-Dap-OH

• 产品号: 15402
• CAS号: 73259-81-1
• 分子式: C8H16N2O4
• 分子量: 204.22364
• 纯 度: ≥98.0% (TLC)

产品别名

• 标题: Boc-Dap-OH
• IUPAC标准名: (2S)-3-amino-2-{[(tert-butoxy)carbonyl]amino}propanoic acid
• IUPAC传统名: (2S)-3-amino-2-[(tert-butoxycarbonyl)amino]propanoic acid
• 别名: (S)-3-氨基-2-(叔丁氧羰基氨基)丙酸; (S)-3-Amino-2-(tert-butoxycarbonylamino)propanoic acid; (S)-2-[(tert-Butoxycarbonyl)amino]-3-aminopropionic acid; (S)-3-Amino-2-(tert-butoxycarbonyl)aminopropionic acid; Nα-BOC-(S)-β-aminoalanine; Nα-Boc-L-β-aminoalanine; N2-(tert-Butoxycarbonyl)-(S)-2,3-diaminopropionic acid; N2-tert-Butoxycarbonyl-L-2,3-diaminopropionic acid; Boc-Dpr-OH; 3-Amino-(tert-butoxycarbonyl)-L-alanine; Nα-Boc-L-2,3-diaminopropionic acid; 3-氨基-(叔丁氧羰基)-L-丙氨酸; Nα-Boc-L-2,3-二氨基丙酸

产品登记号

• CAS号: 73259-81-1
• PubChem SID: 24849398
• MDL号: MFCD00236843
• Beilstein号: 4182136

产品性质

• Empirical Formula (Hill Notation): C8H16N2O4
• 杂质: ~3% water
• 纯度: ≥98.0% (TLC)
• 熔点: 210 °C (dec.)
• 比旋光度: [α]20/D +5.5±1°, c = 1% in methanol: water (1:1)
• 个人保护装置: Eyeshields, Gloves, type N95 (US), type P1 (EN143) respirator filter
• 德国WGK号: 3

产品详细信息

详细说明 (English)

Other Notes
Monoprotected derivative of DAP; used e.g. in the synthesis of glucosamine synthase inhibitors,6,7 a myosin kinase inhibitor.8 Preparation of peptides with metal complexing groups.9
Packaging
1, 5 g in glass bottle
Application
Reactant for:
• Protein assembly directed by synthetic molecular recognition motifs1
• Solid phase synthesis of gramicidin S cyclic analogs with antibiotic and hemolytic activities2
• Synthesis of HCV protease inhibitor modified analogs3
• Solid phase synthesis of peptidic V1a receptor agonists4
• Directed peptide assembly at lipid-water interface5

详细说明 (简体中文)

Other Notes
DAP 单保护衍生物；用于例如，合成氨基葡萄糖合成酶抑制剂6,7（一种肌球蛋白激酶抑制剂）。8 与金属络合基团反应制备多肽。9
包装
1, 5 g in glass bottle
Application
Reactant for:
• Protein assembly directed by synthetic molecular recognition motifs1
• Solid phase synthesis of gramicidin S cyclic analogs with antibiotic and hemolytic activities2
• Synthesis of HCV protease inhibitor modified analogs3
• Solid phase synthesis of peptidic V1a receptor agonists4
• Directed peptide assembly at lipid-water interface5